News

‍The May 2023 edition of The Spark features the latest Lantern updates including:

• Submitted LP-184’s IND application to the FDA - A Phase 1A Trial Expected to Launch During Q2 2023
• Established New Collaboration with Bielefeld University to Develop Breakthrough Antibody Drug Conjugates (ADCs) using AI
• Dosed Initial Patients in the Harmonic™ Clinical Trial - A Phase2 Study for Never Smokers with Lung Cancer
• RADR® Machine Learning Models Accurately Predict Clinical Trial Patient Responses - Results Presented at ASCO 2023 with Actuate Therapeutics
• Developed Industry Leading AI Algorithms to Predict AnyCompound’s Ability to Cross the Blood-Brain Barrier - a MajorProblem for Drug Development in Neuro-Oncology.
• In Case You Missed It: Replays of our Q1 Call and RecentInvestor Conferences are Now Available.

‍

‍

The March 2023 edition of The Spark features the latest company updates including:

• The Phase 2 Harmonic™ Trial Activates 5th Trial Site and Secures 1st Consented Patient
• Lantern has Completed LP-184’s IND Enabling Studies & Phase 1A Trial Launch Targeted for Q2 2023
• Starlight Therapeutics Launched to Advance LP-184’s Clinical Development Exclusively for CNS & Brain Cancers
• Lantern and TTC Oncology Ink New AI-Driven Collaboration in Breast Cancer
• Future RADR® Roadmap to Focus on the Development of Antibody Drug Conjugates
• Learn More About Synthetic Lethality - The Unique Mechanism Behind Several of Lantern’s Drug Candidates
• In Case You Missed It: A Replay of our Q4 2022 Earnings Call Is Now Available

The January 2023 edition of The Spark features the latest companyupdates including:

• Lantern granted an FDA Orphan Drug Designation (ODD) forLP-284 to treat mantle cell lymphoma - 4th overall ODD.
• The Harmonic™ trial, for never-smokers with NSCLC, expandssites across the US with 11th location added in Texas.
• First of its kind, patient focused, iPhone app launched for theHarmonic™ trial.
• Positive pre-IND FDA meeting solidifies the path for LP-184’sIND submission and clinical trial launch in Q2 2023.

The December 2022 edition of The Spark features exciting new company updates including:

• Lantern was ranked as one of the top 20 most productive AI drug development companies worldwide.
• Harmonic™ trial adds 8 new locations across NY to bolster patient recruitment with New York Cancer and Blood Specialists
• Interviews of never-smokers with lung cancer highlights needs for new therapies and trials targeted for never-smokers
• Expansion of LP-184’s development for triple negative breast cancer increases its long-term value
• New positive LP-284 data for mantle cell lymphoma (MCL) advances it towards a Phase 1 trial in 2023

This month’s newsletter features novel research from our RADR® AI platform and lays a foundation for how AI can be applied to discover new indications for cancer drugs in record times and at significantly reduced costs.

• The research was done in collaboration with the National Cancer Institute (NCI) that was recently published in Frontiers in Drug Discovery.
• The publication highlights how large scale biological data, artificial intelligence, and machine learning were leveraged to rapidly identify Atypical Teratoid Rhabdoid Tumor (ATRT) as an indication for Lantern’s drug candidate LP-184.
• In just over a year, Lantern has advanced its ATRT program for LP-184 from initial in silico RADR® AI insight, to in vitro and in vivo wet lab validation, to discussions with Key Opinion Leaders about a Phase 1 pediatric clinical trial design.
• ATRT is a rare and highly malignant childhood central nervous system cancer with no standard-of-care (SOC) therapy. LP-184’s efficacy for ATRT could fill a void for this cancer with urgent and unmet clinical needs.
• A PDF of the new publication can be downloaded here, or read online on the Frontiers in Drug Discovery website.

In the second edition of the Lantern Pharma Newsletter you will find:

• Phase 2 Harmonic™ clinical trial for LP-300 continues momentum with the activation of two cancer center sites and the launch of a patient-focused website
• Lantern Pharma to host KOL webinar Sept. 22nd for Childhood Cancer Awareness Month
• RADR® insights lead to accelerating the development of Actuate Therapeutics drug candidate Elraglusib
• Scientific and investor conferences Lantern will be attending in Q3/Q4

We are pleased to present our new newsletter and outreach initiative to deliver succinct and frequent information about our company.

‍
Feel free to send us your feedback by clicking on the thumb emoji in the email footer, or by emailing us at newsletter@lanternpharma.com.
Happy reading!

‍